Beyond GLP-1: Which Peptides Are Actually Changing Men's Lives in 2026

GLP-1 receptor agonists like Wegovy and Zepbound dominate the weight-loss conversation, but several other peptide classes are producing meaningful — sometimes dramatic — results for men who can't tolerate, access, or fully respond to semaglutide or tirzepatide. The evidence ranges from robust phase III trial data to modest community-reported outcomes, and the distinction matters.

Setmelanotide: The Most Evidence-Backed Non-GLP-1 Peptide

For men with rare genetic or acquired obesity, setmelanotide (IMCIVREE) has delivered results that no GLP-1 can match in the right patient. The drug works as an MC4 receptor agonist — essentially bypassing broken hypothalamic circuitry upstream of where semaglutide acts. In the pivotal BBS/Alström syndrome trial, 32.3% of patients aged 12 and older lost at least 10% of baseline body weight after one year, and 62.5% of Bardet-Biedl patients achieved a ≥25% reduction in hunger scores [2][3]. For men who've spent their lives fighting hyperphagia, those aren't incremental improvements.

The phase III TRANSCEND trial — targeting acquired hypothalamic obesity after craniopharyngioma or brain injury — produced a mean BMI reduction of 16.5% versus a 3.3% increase in the placebo arm at 52 weeks, with 80% of setmelanotide patients hitting the ≥5% BMI threshold [4]. The FDA has now extended the IMCIVREE label to cover acquired hypothalamic obesity in patients four years and older [8]. This is not a wellness-clinic peptide. It's a precision pharmacology tool for men whose weight problem originates in damaged or defective neural circuitry [6].

Tesamorelin and GH-Related Peptides: Visceral Fat, Not Scale Weight

Tesamorelin — a growth hormone-releasing hormone analogue approved as Egrifta — doesn't produce dramatic weight loss. What it does is selectively reduce visceral adipose tissue, particularly in men with HIV-associated lipodystrophy, where abdominal fat accumulation is both metabolically dangerous and psychologically distressing. Clinical data show consistent reductions in VAT of 15–20% after 26 weeks, with improvements in triglycerides and IGF-1, without meaningful changes in subcutaneous fat or lean mass [12][13]. For men using weight management programs alongside antiretroviral therapy, tesamorelin addresses a body composition problem that GLP-1s weren't designed for.

Off-label peptides like CJC-1295/ipamorelin are widely used in men's health clinics for body recomposition. Community reports cluster around improved sleep quality, faster recovery, and modest fat loss — not the 15–20% weight reductions seen in SURMOUNT-1 with tirzepatide or STEP-1 with semaglutide, both published in NEJM [3][5]. The honest assessment: GH secretagogue peptides produce real but limited body composition shifts. Men expecting GLP-1-level weight loss will be disappointed. Men looking for a recovery and recomposition edge alongside structured training report more satisfaction.

If you're weighing whether a telehealth provider can connect you with evidence-based peptide protocols, compare GLP-1 and peptide-prescribing platforms at our online provider directory before committing to a vendor.

Frequently asked questions

What is setmelanotide and who actually benefits from it?

Setmelanotide (IMCIVREE) is an MC4 receptor agonist approved for obesity caused by specific genetic defects — POMC, PCSK1, and LEPR deficiencies, Bardet-Biedl syndrome, and now acquired hypothalamic obesity — not general-population weight loss. In the TRANSCEND trial, patients with acquired hypothalamic obesity saw a mean BMI reduction of 16.5% versus placebo at 52 weeks [4]. Men without a confirmed MC4 pathway defect or hypothalamic injury are unlikely to see meaningful response; this isn't a drug to obtain off-label for routine fat loss.

How do non-GLP-1 peptides compare to Wegovy or Zepbound for weight loss?

For most men, Wegovy (semaglutide) and Zepbound (tirzepatide) still produce larger and more reliable weight loss than any currently available non-GLP-1 peptide — roughly 15% and 20%+ body weight respectively in large trials. You can read a direct breakdown in our semaglutide vs. tirzepatide comparison for men. Non-GLP-1 peptides fill specific gaps: setmelanotide for hypothalamic/genetic obesity, tesamorelin for HIV-associated VAT, and GH secretagogues for modest recomposition in otherwise healthy men.

Can I get tesamorelin or setmelanotide through a telehealth provider?

Setmelanotide requires a confirmed genetic or clinical diagnosis and is dispensed through a specialty pharmacy network — it's not available through standard telehealth weight-loss platforms. Tesamorelin is FDA-approved for HIV-associated lipodystrophy specifically; off-label prescribing exists but is less common. For evidence-based GLP-1 and peptide prescribing through telehealth, Hims offers supervised weight management programs that may include compounded semaglutide or tirzepatide where clinically appropriate. For context on how retatrutide — the next-generation triple agonist — fits into this landscape, see our [six-month retatrutide data review](/blog/six-months-on-retatrutide-what-the-phase-2-data